You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
精華製藥(002349.SZ):在倍他替尼上市銷售後 公司享有其淨利潤的12%
格隆匯 03-23 17:49

格隆匯3月23日丨精華製藥(002349.SZ)公佈,2022年3月23日,公司與蘇州韜略、美國AspediaLLC公司簽署了《技術開發(合作)合同書之補充合同》,各方協商同意倍他替尼的後續資金投入、研發、商業化由蘇州韜略主導,在倍他替尼上市銷售後,公司享有其淨利潤的12%。

公司對倍他替尼項目的研發耗時較長,研究進度不及預期,項目不屬於公司發展重點。蘇州韜略擁有小分子抗癌藥豐富的臨牀研究資源和技術優勢,能加快項目推進,簽署該補充協議有利於發揮各自優勢,減少公司研發風險,獲取長期收益。該項目支出已記入歷年損益,不會對公司當期淨利潤產生重大影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account